<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118376</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-1</org_study_id>
    <nct_id>NCT02118376</nct_id>
  </id_info>
  <brief_title>Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status</brief_title>
  <official_title>Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status in Female Patients With Type 2 Diabetes and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes,
      reduce liver fat content, improve the inflammation state
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a treatment for type 2 diabetesGlucagon like peptide -1 (Glucan-like peptide-1, GLP-1)
      receptor agonists plays the role of promoting insulin secretion, inhibiting glucagon
      secretionï¼Œand also has the central and peripheral effects,it can inhibit appetite,reduce
      weight.GLP-1 receptor agonists promote fat redistribution in obese women with type 2
      diabetes, reduce liver fat content, improve the inflammation state
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dual energy X-ray absorptiometry</measure>
    <time_frame>3 month</time_frame>
    <description>fat distribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lab testing</measure>
    <time_frame>3 month</time_frame>
    <description>inflammation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>lab testing</measure>
    <time_frame>3 months</time_frame>
    <description>liver function</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exenatide, 5ug, bid, 3months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>5ug bid,Subcutaneous injection</description>
    <arm_group_label>exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of overweight and type 2 diabetes mellitus

        Exclusion Criteria:

          -  Poor body condition (severe liver and kidney dysfunction)

          -  Unknown causes of pancreatitis, chronic pancreatitis, pancreatic resection, stomach
             operation, malignant tumor, previous use of systemic corticosteroids (local or
             inhalation of exceptions) heart function or niacin, incomplete

          -  serious endocrine disease

          -  genetic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qu Shen</last_name>
    <role>Study Director</role>
    <affiliation>Shang Tenth People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Jie</last_name>
    <phone>13916674766</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Tenth People' Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>April 16, 2014</last_update_submitted>
  <last_update_submitted_qc>April 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Manna</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>obesity; fat distribution; inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

